EP
PHAT icon

Essential Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Essential Partners’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6
Closed -$100 – 2953
2025
Q4 		$100 Buy
+6
New +$86 ﹤0.01% 2553

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Essential Partners's PHAT Position: Q1 2026 in Review

Essential Partners sold out of Phathom Pharmaceuticals (PHAT) in Q1 2026, closing a stake of 6 shares — an estimated $100 sold.

Essential Partners first reported a position in PHAT in Q4 2025 and held it in 1 quarter. The position peaked at $100 in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Essential Partners reported no remaining Phathom Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Essential Partners sold 6 Phathom Pharmaceuticals shares in Q1 2026, an estimated $100.
  • Essential Partners first reported a position in Phathom Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Essential Partners's Phathom Pharmaceuticals position peaked at $100 in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Essential Partners's 13F filing for Q1 2026, filed 21 May 2026.